Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

Endocrinology

Volumn 145, Issue 4, 2004, Pages 1996-2005

  Ke, Hua Zhu ^a   Foley, George L ^a   Simmons, Hollis A ^a   Shen, Victor ^b   Thompson, David D ^a  

^a PFIZER INC   (United States)

^b SkeleTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEOXYPYRIDINOLINE; LASOFOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; ENERGY; FEMALE; HISTOLOGY; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE COMPUTER ASSISTED TOMOGRAPHY; RAT; TIBIA; TRABECULAR BONE; UTERUS; UTERUS WEIGHT;

AMINO ACIDS; ANIMALS; BIOMECHANICS; BONE AND BONES; COMPRESSIVE STRENGTH; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENITALIA, FEMALE; LUMBAR VERTEBRAE; ORGAN SIZE; OSTEOCALCIN; OVARIECTOMY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; TIBIA; TOMOGRAPHY, X-RAY COMPUTED; UTERUS;

EID: 1642489155     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1481     Document Type: Article

References (32)

1. Melton III LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL 1992 How many women have osteoporosis? J Bone Miner Res 7:1005-1010
2. Berg RL, Casell JS, eds 1990 Osteoporosis. The second fifty years: promoting health and preventing disability. Washington DC: National Academy Press; 76-100
3. Riggs BL, Melton III LJ 1992 The prevention and treatment of osteoporosis. N Engl J Med [Erratum (1993) 328:65] 327:620-627
4. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 Estrogen replacement therapy and fractures in older women. Study of Osteoporosis Fractures Research Group. Ann Intern Med 122:9-16
5. Maxim P, Ettinger B, Spitalny GM 1995 Fracture protection provided by long-term estrogen treatment. Osteop Int 5:23-29
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
7. Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, Stefanick ML, Pickar JH 2002 Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol [Erratum (2003) 101:619] 100:1209-1218
8. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, Women's Health Initiative Investigators 2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854.
9. Food and Drug Administration 2003 FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data. Rockville: Food and Drug Administration
10. Riggs BL, Hartmann LC 2003 Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med [Erratum (2003) 348:1192] 348:618-629
11. Johnston Jr CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath III H, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450
12. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA [Erratum (1999) 282:2124] 282:637-645
13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC 1999 The effects of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA [Erratum (1999) 282:2124] 281:2189-2197
14. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WSS, Cameron KO, Rosati RL, Brown TA, DaSilva-Jardine P, Thompson DD 1998 Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 139: 2068-2076
15. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD 2000 Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 141:1338-1344
16. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD 2001 Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 16:765-773
17. Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD 2001 LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 61:8685-8688
18. Bolognese M, Moffett A, Lee A, Wolter K, Day W, Somayaji V, Gordon P 2003 Lasofoxifene is superior to raloxifene in the prevention of bone loss in post-menopausal women: 1-year results. Bone 32 (Suppl 5):S93 (Abstract)
19. Frost HM, Jee WS 1992 On the rat model of human osteopenias and osteoporoses. Bone Miner 18:227-236
20. Kalu DN 1991 The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-191
21. Wronski TJ, Yen CF 1991 The ovariectomized rat model as an animal model for postmenopausal bone loss. Cells Materials 3(Suppl 1):69-74
22. Food and Drug Administration 1994 FDA guidelines for preclinical and clinical evaluation of agents used for the treatment or prevention of postmenopausal osteoporosis. Rockville: Food and Drug Administration
23. Baron R, Vignery A, Neff L, Silverglate A, Maria AS 1983 Processing of undecalcified bone specimens for bone histomorphometry. In: Recker RR, ed. Bone histomorphometry: techniques and interpretation. Boca Raton: CRC Press; 13-36
24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
25. Jee WSS, Li XJ, Inoue J, Jee KW, Haba T, Ke HZ, Setterberg RB, Ma YF 1997 Histomorphometric assay of the growing long bone. In: Takahashi H, ed. Handbook of bone morphology. Niigata City: Nishimusa; 87-112
26. Brown HR, Leininger JR 1992 Alterations of the uterus. In: Mohr U, Dungworth DL, Capen CC, eds. Pathobiology of the aging rat. Washington DC: ILSI Press; 377-388
27. Gopinath C 1992 Susceptibility of the uterus to toxic substances. In: Mohr U, Dungworth DL, Capen CC, eds. Pathobiology of the aging rat. Washington DC: ILSI Press; 389-394
28. van Zwieten MJ, HogenEsch H, Majka JA, Boorman GA 1994 Nonneoplastic and neoplastic lesions of the mammary gland. In: Mohr U, Dungworth DL, Capen CC, eds. Pathobiology of the aging rat. Washington DC: ILSI Press; 459-475
29. Ke HZ, Brown TA, Thompson DD 2002 Lasofoxifene (CP-533,536), a novel selective estrogen receptor modulator, in preclinical studies. J Am Aging Assoc 25:87-100
30. Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee WS, Turner CH, Sato M 2002 Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17:2256-2264
31. Wronski TJ, Dann LM, Scott KS, Cintron M 1989 Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360-366
32. Sato M, Rippy MK, Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905-912